[2,2-dimethyl-4-oxo-4-(3-oxobutylamino)butyl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: [2,2-dimethyl-4-oxo-4-(3-oxobutylamino)butyl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
• 化学式: C₃₀H₄₇NO₄
• 分子量: 485.7
• InChiKey: PGDMMDUPKBOYBJ-WMPRHZDHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  35
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  72.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME AND LIPID DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DU SYNDROME MÉTABOLIQUE ET DE TROUBLES LIPIDIQUES
  申请人：KANDULA MAHESH

  公开号：WO2014091465A2

  公开（公告）日：2014-06-19

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of metabolic syndrome and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes, hypertriglyceridemia, dyslipidemia, obesity and atherosclerosis.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORTHOSTASIS AND NEUROLOGICAL DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE L'ORTHOSTASIE ET DE MALADIES NEUROLOGIQUES
  申请人：KANDULA MAHESH

  公开号：WO2014174425A2

  公开（公告）日：2014-10-30

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for the treatment of orthostasis and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurogenic orthostatic hypotension (NOH), multiple system atrophy (MSA), familial amyloid polyneuropathy (FAP), pure autonomic failure (PAF), Parkinson's disease (PD), Intradialytic hypotension (IDH) or hemodialysis- induced hypotension, Hypotension associated with fibromyalgia syndrome (FMS) and chronic fatigue syndrome (CFS).
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND RENAL COMPLICATIONS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DE MALADIES NEUROLOGIQUES ET DE COMPLICATIONS RÉNALES
  申请人：KANDULA MAHESH

  公开号：WO2014203198A2

  公开（公告）日：2014-12-24

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological diseases and renal complications may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of renal transplantation, preservation of renal function in rhabdomyolysis secondary to crush injuries and compartment syndrome, Bowel preparation before colorectal surgery, colonoscopy, and barium enemas, promotion of urinary excretion of toxic material, chronic Pain, diabetic neuropathy, seizures, Creutzfeld- Jacob disease, multiple sclerosis, Parkinson's, Obesity, bipolar depression, partial-onset seizures and spasm.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND THE ASSOCIATED ABDOMINAL CRAMPING<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DU SYNDROME DU CÔLON IRRITABLE ET DES CRAMPES ABDOMINALES ASSOCIÉES
  申请人：KANDULA MAHESH

  公开号：WO2015001499A2

  公开（公告）日：2015-01-08

  The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of irritable bowel syndrome and the associated abdominal cramping may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of coeliac disease, fructose malabsorption, mild infections, parasitic infections like giardiasis, several inflammatory bowel diseases, bile acid malabsorption, functional chronic constipation, small intestinal bacterial overgrowth, and chronic functional abdominal pain.